School of Gastrointestinal Oncology | Conference

Dr. Grothey on the Differences Between Available ctDNA Assays in CRC

March 29th 2021

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

Racial Disparities Persist in GI Cancers and Beyond

March 24th 2021

Racial disparities affecting all aspects of patient care are a major issue across cancer types, including for patients with gastrointestinal cancers.

Messersmith Makes Sense of the Novel Approaches on the Rise in GI Malignancies

March 23rd 2021

The pipeline of new agents in gastrointestinal cancers is robust, with the emergence of several antibody-drug conjugates, KRAS G12C inhibitors, and novel TKI/immune checkpoint inhibitor combinations.

Dr. Choti on Challenging Treatment Decisions in NETs

March 23rd 2021

Michael A. Choti, MD, discusses challenging treatment decisions in patients with neuroendocrine tumors.

ctDNA Possesses the Potential to Revolutionize Care in CRC and Beyond

March 23rd 2021

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

The Future of Biliary Tract Treatment Lies in Molecular Profiling

March 22nd 2021

Although the genetic makeup of biliary tract cancer is rich, only recently has the field been able to show the benefit of treating patients with effective targeted agents, such as pemigatinib and ivosidenib in the advanced setting.

Debate Continues on Optimal Neoadjuvant Regimen in Resectable Pancreatic Cancer

April 2nd 2020

Michael A. Choti, MD, MBA, FACS, discusses the role of radiation therapy in neoadjuvant therapy for resectable pancreatic cancer, the many benefits of neoadjuvant therapy over up-front surgery, and minimally invasive surgical procedures that are coming to the forefront in this disease.

Novel Approaches to Build on Checkpoint Inhibition in GI Cancers

April 1st 2020

Despite some success stories, most gastrointestinal cancers do not respond to single-agent, or even double-agent, immune checkpoint inhibition, Neeha Zaidi, MD, said in a presentation during the 5th Annual School of Gastrointestinal Oncology™ (SOGO®) conference.

Targeted Agents Show Promise in Cholangiocarcinoma

March 31st 2020

Cholangiocarcinoma is both rare and aggressive, and the current systemic standard of care, gemcitabine plus cisplatin, produces only modest results.

Management, Etiology of Younger Patients With CRC Require Deeper Understanding

March 31st 2020

The etiology and overall management of patients with early-onset colorectal cancer needs to be better understood and personalized, respectively, explained Andrea Cercek, MD, in a presentation during the 5th Annual School of Gastrointestinal Oncology™.

Dr. Shah on the Role of Immunotherapy in Gastroesophageal Cancer

March 21st 2020

Manish A. Shah, MD, discusses the role of immunotherapy in gastroesophageal cancer.

Dr. Choti on the Benefits of Neoadjuvant Chemotherapy in Pancreatic Cancer

March 21st 2020

Michael A. Choti, MD, discusses the benefit of neoadjuvant chemotherapy in pancreatic cancer.

Dr. Marshall on Challenges in CRC Treatment

March 21st 2020

John L. Marshall, MD, discusses the challenges in the colorectal cancer field.

Dr. Geschwind on Locoregional Therapy for Patients With Liver Cancer

April 26th 2016

Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).

Novel Agents on Horizon for Advanced HCC

April 26th 2016

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma, including a host of targeted therapies and various immune checkpoint inhibitors.

Immunotherapy Doubts Fading in GI Cancers

April 26th 2016

Immunotherapy approaches are showing early signs of activity against a range of gastrointestinal cancers, defying the skeptical view that these tumors would not respond to the emerging agents succeeding in other malignancies.

Dr. Douglas Evans on Neadjuvant Therapy for Pancreas Cancer

April 26th 2016

Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

Multidisciplinary Treatment a Growing Need in Liver Cancer

April 26th 2016

Michael Choti, MD, explains the impact of advancements in the treatment of patients with liver cancer and how building on them will require all oncology professionals to work as a team.

Precision Medicine Vital to Value-Based GI Cancer Care

April 23rd 2016

Cancer care is shifting from a consumption to a value-based model, and precision oncology should play a vital role in that process by helping to deliver more effective therapies with more manageable pricing profiles.

Numerous Frontline CRC Options Allow Individualized Approach

April 23rd 2016

Given the numerous available treatment options, the most important issue in frontline colorectal cancer care is clarifying the goals of therapy.